A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma

A Gynecologic Oncology Group Study

Robert S. Mannel, Mark F. Brady, Elise C. Kohn, Parviz Hanjani, Masamichi Hiura, Roger Lee, Koenraad De Geest, David E. Cohn, Bradley J. Monk, Helen Michael

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment to either observation or maintenance paclitaxel 40 mg/m2/week × 24 weeks. Recurrence required clinical or radiological evidence of new tumor. Results: There were 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients. At least 3 cycles of treatment were administered to 524/542 (97%) of patients, and among those assigned to maintenance paclitaxel, 80% completed the regimen. The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p <0.001). The cumulative probability of recurring within 5 years for the maintenance paclitaxel regimen is 20% vs. 23% for surveillance (hazard ratio 0.807; 95% CI: 0.565-1.15). The probability of surviving 5 years was 85.4% and 86.2%, respectively. Conclusion: Maintenance paclitaxel at 40 mg/m2/week × 24 weeks added to standard dose AUC6 and paclitaxel 175 mg/m2 × 3 doses provides no significant increase in RFI.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalGynecologic Oncology
Volume122
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Maintenance
Observation
Carcinoma
Recurrence
Naphazoline
Peripheral Nervous System Diseases
Ovarian Neoplasms
Area Under Curve
Fever
Pathology
Safety
Incidence
Infection

Keywords

  • early stage ovarian carcinoma
  • GOG
  • IV carboplatin and paclitaxel

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma : A Gynecologic Oncology Group Study. / Mannel, Robert S.; Brady, Mark F.; Kohn, Elise C.; Hanjani, Parviz; Hiura, Masamichi; Lee, Roger; De Geest, Koenraad; Cohn, David E.; Monk, Bradley J.; Michael, Helen.

In: Gynecologic Oncology, Vol. 122, No. 1, 07.2011, p. 89-94.

Research output: Contribution to journalArticle

Mannel, Robert S. ; Brady, Mark F. ; Kohn, Elise C. ; Hanjani, Parviz ; Hiura, Masamichi ; Lee, Roger ; De Geest, Koenraad ; Cohn, David E. ; Monk, Bradley J. ; Michael, Helen. / A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma : A Gynecologic Oncology Group Study. In: Gynecologic Oncology. 2011 ; Vol. 122, No. 1. pp. 89-94.
@article{f92beff187bf4b6cb7041531562d1983,
title = "A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: A Gynecologic Oncology Group Study",
abstract = "Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment to either observation or maintenance paclitaxel 40 mg/m2/week × 24 weeks. Recurrence required clinical or radiological evidence of new tumor. Results: There were 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients. At least 3 cycles of treatment were administered to 524/542 (97{\%}) of patients, and among those assigned to maintenance paclitaxel, 80{\%} completed the regimen. The incidence of grade 2 or worse peripheral neuropathy (15.5{\%} vs. 6{\%}), infection/fever (19.9{\%} vs. 8.7{\%}), and dermatologic events (70.8{\%} vs. 52.1{\%}) was higher on the maintenance regimen (p <0.001). The cumulative probability of recurring within 5 years for the maintenance paclitaxel regimen is 20{\%} vs. 23{\%} for surveillance (hazard ratio 0.807; 95{\%} CI: 0.565-1.15). The probability of surviving 5 years was 85.4{\%} and 86.2{\%}, respectively. Conclusion: Maintenance paclitaxel at 40 mg/m2/week × 24 weeks added to standard dose AUC6 and paclitaxel 175 mg/m2 × 3 doses provides no significant increase in RFI.",
keywords = "early stage ovarian carcinoma, GOG, IV carboplatin and paclitaxel",
author = "Mannel, {Robert S.} and Brady, {Mark F.} and Kohn, {Elise C.} and Parviz Hanjani and Masamichi Hiura and Roger Lee and {De Geest}, Koenraad and Cohn, {David E.} and Monk, {Bradley J.} and Helen Michael",
year = "2011",
month = "7",
doi = "10.1016/j.ygyno.2011.03.013",
language = "English (US)",
volume = "122",
pages = "89--94",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma

T2 - A Gynecologic Oncology Group Study

AU - Mannel, Robert S.

AU - Brady, Mark F.

AU - Kohn, Elise C.

AU - Hanjani, Parviz

AU - Hiura, Masamichi

AU - Lee, Roger

AU - De Geest, Koenraad

AU - Cohn, David E.

AU - Monk, Bradley J.

AU - Michael, Helen

PY - 2011/7

Y1 - 2011/7

N2 - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment to either observation or maintenance paclitaxel 40 mg/m2/week × 24 weeks. Recurrence required clinical or radiological evidence of new tumor. Results: There were 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients. At least 3 cycles of treatment were administered to 524/542 (97%) of patients, and among those assigned to maintenance paclitaxel, 80% completed the regimen. The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p <0.001). The cumulative probability of recurring within 5 years for the maintenance paclitaxel regimen is 20% vs. 23% for surveillance (hazard ratio 0.807; 95% CI: 0.565-1.15). The probability of surviving 5 years was 85.4% and 86.2%, respectively. Conclusion: Maintenance paclitaxel at 40 mg/m2/week × 24 weeks added to standard dose AUC6 and paclitaxel 175 mg/m2 × 3 doses provides no significant increase in RFI.

AB - Objective: To compare the recurrence-free interval (RFI) and safety profile in patients with completely resected high-risk early-stage ovarian cancer treated with intravenous (IV) carboplatin and paclitaxel with or without maintenance low-dose paclitaxel for 24 weeks. Methods: Eligibility was limited to patients with stage IA/B (grade 3 or clear cell), all IC or II epithelial ovarian cancer. All patients were to receive carboplatin AUC 6 and paclitaxel 175 mg/m2 q3 weeks × 3 courses with random assignment to either observation or maintenance paclitaxel 40 mg/m2/week × 24 weeks. Recurrence required clinical or radiological evidence of new tumor. Results: There were 571 patients enrolled onto this study, of whom 29 were deemed ineligible due to inappropriate stage or pathology, leaving 542 patients. At least 3 cycles of treatment were administered to 524/542 (97%) of patients, and among those assigned to maintenance paclitaxel, 80% completed the regimen. The incidence of grade 2 or worse peripheral neuropathy (15.5% vs. 6%), infection/fever (19.9% vs. 8.7%), and dermatologic events (70.8% vs. 52.1%) was higher on the maintenance regimen (p <0.001). The cumulative probability of recurring within 5 years for the maintenance paclitaxel regimen is 20% vs. 23% for surveillance (hazard ratio 0.807; 95% CI: 0.565-1.15). The probability of surviving 5 years was 85.4% and 86.2%, respectively. Conclusion: Maintenance paclitaxel at 40 mg/m2/week × 24 weeks added to standard dose AUC6 and paclitaxel 175 mg/m2 × 3 doses provides no significant increase in RFI.

KW - early stage ovarian carcinoma

KW - GOG

KW - IV carboplatin and paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=79957725785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957725785&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.03.013

DO - 10.1016/j.ygyno.2011.03.013

M3 - Article

VL - 122

SP - 89

EP - 94

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -